Education
About Us
Working with TipRanks
Follow Us
Raily Aesthetic Medicine International Holdings Limited (HK:2135)
:2135
2135 Stock Chart & Stats
HK$0.17
<HK$0.01(0.99%)
At close: 4:00 PM EST
HK$0.17
<HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.10 - HK$0.20
Previous CloseN/A
Volume240.00K
Average Volume (3M)289.64K
Market Cap
HK$83.56M
Enterprise ValueHK$111.09M
Total Cash (Recent Filing)HK$35.73M
Total Debt (Recent Filing)HK$72.96M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.05
P/FCF Ratio-0.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Secular Market Growth In Aesthetic MedicineRaily sits in a structurally expanding market for non- and minimally invasive aesthetic treatments. Long-term demographic and consumer-preference trends favor less-invasive procedures, enlarging the addressable market and supporting sustained demand for clinics, services, and repeat clients.
Fee-for-service Model With Recurring Patient RevenueA fee-for-service model with repeat clients and referrals supports predictable unit economics and customer lifetime value. Cross-selling products and add-on treatments can raise per-patient revenue, making topline durability less dependent on single large contracts.
Positive Operating Cash Conversion Versus Accounting LossesEven with accounting losses, positive operating cash flow relative to net income suggests core clinic operations generate cash. This operational cash conversion provides a foundation to fund working capital and targeted investments while management addresses profitability and cost structure.
Bears Say
Persistent Net Losses And Margin PressureSustained negative margins and recurring losses signal structural profitability issues. Continued negative EBIT/EBITDA limits reinvestment capacity, undermines shareholder returns, and raises the bar for necessary revenue or efficiency improvements to reach sustainable profitability.
Rising Leverage And Debt RiskHigher leverage reduces financial flexibility and increases interest and refinancing risk. For a service business reliant on stable cash flows, rising debt amplifies vulnerability to revenue shortfalls and constrains capital available for clinic expansion or technology upgrades.
Negative And Worsening Free Cash FlowWorsening free cash flow erodes liquidity and forces dependence on external financing or asset sales. Persistent FCF deficits limit the company's ability to invest in growth initiatives, retain staff, and maintain equipment, threatening long-term operational resilience.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.10 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$83.56M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Aug 29, 2025. The company reported -HK$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.015.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of -HK$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.847%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Raily Aesthetic Medicine International Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.26%
12-Months-Change
Fundamentals
Return on Equity
-51.07%
Trailing 12-Months
Asset Growth
-24.40%
Trailing 12-Months
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited (2135) is a prominent player in the aesthetic medicine sector, specializing in providing a range of aesthetic and cosmetic services. The company operates in the rapidly growing field of non-invasive and minimally invasive treatments, including injectables, laser therapies, and skin rejuvenation procedures. With a strategic focus on enhancing patient experiences and outcomes, Raily Aesthetic Medicine leverages advanced technologies and skilled practitioners to cater to an expanding clientele seeking aesthetic enhancements and skincare solutions.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
MediNet Group Ltd.
―
Medicskin Holdings Ltd.
―
Republic Healthcare Limited
―
RMH Holdings Limited
―